Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07333-7 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Toshimi Takano und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy, Carboplatin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Breast Cancer Research Group.
Abstract (Originalsprache)
Purpose
The randomized phase 2 Neo-peaks study examined usefulness of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) following docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) as compared with the standard TCbHP regimen. We previously reported that pCR rate after neoadjuvant therapy tended to be higher with TCbHP followed by T-DM1 + P. We conducted an exploratory analysis of prognosis 5 years after surgery.
Methods
Neoadjuvant treatment with TCbHP (6 cycles; group A), TCbHP (4 cycles) followed by T-DM1 + P (4 cycles; group B), and T-DM1 + P (4 cycles; group C, + 2 cycles in responders) were compared. Group C non-responders after 4 cycles were switched to an anthracycline-based regimen. We evaluated 5-year disease-free survival (DFS), distant DFS (DDFS), and overall survival (OS).
Results
Data from 203 patients (50, 52, and 101 in groups A–C, respectively) were analyzed. No significant intergroup differences were found for DFS, DDFS, or OS. The 5-year DFS rates (95% CI) were 91.8% (79.6–96.8%), 92.3% (80.8–97.0%), and 88.0% (79.9–93.0%) in groups A–C, respectively. TCbHP followed by T-DM1 + P and T-DM1 + P with response-guided addition of anthracycline therapy resulted in similar long-term prognosis to that of TCbHP.
Conclusions
In patients who achieved pCR after neoadjuvant therapy with T-DM1 + P, omission of adjuvant anthracycline may be considered, whereas treatment should be adjusted for non-pCR patients with residual disease. T-DM1 + P with response-guided treatment adjustment may be useful for minimizing toxicity. Trial registration number and date of registration UMIN-CTR, UMIN000014649, prospectively registered July 25, 2014. Some of the study results were presented as a Mini Oral session at the ESMO Breast Cancer 2023 (Berlin, Germany, 11–13 May 2023).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
- Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. nmasuda@alpha.ocn.ne.jp.
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. nmasuda@alpha.ocn.ne.jp.
- Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
- Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan.
- Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Förderung
- Japan Breast Cancer Research Group
Zitieren
APA
Takano, T., Masuda, N., Ito, M., Inoue, K., Tanabe, Y., Kawaguchi, K., Yasojima, H., Bando, H., Nakamura, R., Yamanaka, T., Ishida, K., Aruga, T., Yanagita, Y., Tokunaga, E., Aogi, K., Ohno, S., Kasai, H., Kataoka, T. R., Morita, S., & Toi, M. (2024). Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07333-7
Vancouver
Takano T, Masuda N, Ito M, Inoue K, Tanabe Y, Kawaguchi K, et al. Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07333-7
BibTeX
@article{Takano2024,
author = {Takano, Toshimi and Masuda, Norikazu and Ito, Mitsuya and Inoue, Kenichi and Tanabe, Yuko and Kawaguchi, Kousuke and Yasojima, Hiroyuki and Bando, Hiroko and Nakamura, Rikiya and Yamanaka, Takashi and Ishida, Kazushige and Aruga, Tomoyuki and Yanagita, Yasuhiro and Tokunaga, Eriko and Aogi, Kenjiro and Ohno, Shinji and Kasai, Hiroi and Kataoka, Tatsuki R and Morita, Satoshi and Toi, Masakazu},
title = {Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07333-7}
}
EUVIMED